Request Demo

Last update 23 Jan 2025

Distal Bile Duct Adenocarcinoma

Last update 23 Jan 2025

Basic Info

Synonyms

Adenocarcinoma of the Distal Common Bile Duct, Distal Bile Duct Adenocarcinoma, Distal Cholangiocarcinoma

Introduction

An adenocarcinoma that arises from the common bile duct distal to the insertion of the cystic duct.

Drugs associated with Distal Bile Duct Adenocarcinoma

Varlilumab

Target

CD27

Mechanism

CD27 inhibitors

Active Org.

National Cancer Institute [+3]

Originator Org.

Celldex Therapeutics, Inc.

Active Indication

Advanced Bile Duct Carcinoma [+39]

Inactive Indication

Advanced breast cancer [+21]

Drug Highest PhasePhase 2

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Clinical Trials associated with Distal Bile Duct Adenocarcinoma

NCT06717464

/ Active, not recruitingPhase 2IIT

Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract Cancer, Phase II, Single-center, Randomized Controlled Trial

This is a randomized controlled study to evaluate the efficacy and safety of toripalimab plus capecitabine as postoperative adjuvant therapy for patients with resectable advanced extrahepatic biliary tract cancer.

Start Date12 Nov 2024

Sponsor / Collaborator

Tianjin Medical University Cancer Institute and Hospital

NCT05595122

/ RecruitingNot ApplicableIIT

EUS-guided Choledochoduodenostomy for Primary Drainage of Malignant Distal Biliary Obstruction: a Pilot Study Using FCSEMS Through LAMS

A prospective single-centre pilot study investigating the feasibility and safety of EUS-guided choledochostomy as primary drainage strategy in patients with distal malignant biliary obstruction using a FCSEMS through LAMS to reduce stent dysfunction.

Start Date02 Dec 2022

Sponsor / Collaborator

Academic Medical Center University of Amsterdam

[+1]

NL-OMON53481

/ RecruitingNot ApplicableIIT

EUS-guided choledochoduodenostomy for primary drainage of malignant distal biliary obstruction: a pilot study using FCSEMS through LAMS - SCORPION-II-pilot study

Start Date02 Dec 2022

Sponsor / Collaborator-

100 Clinical Results associated with Distal Bile Duct Adenocarcinoma

100 Translational Medicine associated with Distal Bile Duct Adenocarcinoma

0 Patents (Medical) associated with Distal Bile Duct Adenocarcinoma

655

Literatures (Medical) associated with Distal Bile Duct Adenocarcinoma

20 Dec 2024·Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology

[Excerpt from the 2023 European Association for the Study of the Liver practice guidelines: prevention, diagnosis, and treatment of intrahepatic cholangiocarcinoma].

Article

Author: Shang, Y W ; Han, G H

Intrahepatic cholangiocarcinoma (iCCA) occurs within the liver, between the bile duct and the secondary bile duct. It is the second most common primary liver cancer after hepatocellular carcinoma, and its incidence rate is increasing worldwide. The mortality rate is alarming because of its clinical asymptomatic features (often leading to delayed diagnosis), high invasiveness, and treatment resistance. Early diagnosis, molecular pathological biology, accurate staging, and personalized multidisciplinary treatment are current challenges for researchers and physicians. Furthermore, iCCA is difficult to treat due to its high heterogeneity at the clinical, genomic, epigenetic, and molecular levels. However, recent advances in molecular, surgical, and targeted therapies, along with the recognition that the etiology, risk factors, pathophysiology, molecular biology, and clinical management of iCCA differ completely from those of hilar cholangiocarcinoma (pCCA) and distal cholangiocarcinoma (dCCA), have prompted the International Liver Cancer Association and the European Association for the Study of the Liver to commission international specialized experts to draft evidence-based guidelines for physicians involved in the diagnosis, treatment, and prognosis. Herein, the key points of the guidelines are excerpted.

02 Dec 2024·Surgical technology international

Two Cases of Pylorus-Preserving Pancreatoduodenectomy with Remnant Stomach Preservation in Patients Who Have Undergone Proximal Gastrectomy.

Article

Author: Tokumaru, Teppei ; Yoshimatsu, Rika ; Okabayashi, Takehiro ; Tabuchi, Motoyasu ; Matsumoto, Manabu ; Iwata, Jun ; Sakamoto, Shinya

INTRODUCTIONPancreaticoduodenectomy after proximal gastrectomy (PG) presents technical challenges owing to the need to preserve blood flow in the remnant stomach. Considering the oncological factors and preservation of the remnant stomach blood supply, it is crucial to preserve or reconstruct the right gastric artery (RGA) and/or right gastroepiploic artery (RGEA). In cases where the RGEA is preserved, technical considerations for reconstruction arise owing to the poor motility of the remnant stomach.CASE PRESENTATIONA 79-year-old man was diagnosed with pancreatic head cancer and underwent pylorus-preserving pancreatoduodenectomy (PPPD) three years after PG for gastric cancer. The second patient, a 64-year-old man with a history of PG for esophagogastric junction cancer two years prior, was diagnosed with distal cholangiocarcinoma and underwent PPPD. In both cases, preserving the RGEA while ensuring adequate oncological resection margins was considered feasible. We were able to safely preserve the RGA, RGEA, and remnant stomach. The jejunum was mobilized from the right mesocolon, and all anastomoses (pancreatojejunostomy, choledochojejunostomy, and duodenojejunostomy [D-J]) were performed on the proximal side of the transverse mesocolon to minimize the tension on the D-J anastomosis.CONCLUSIONPancreatoduodenectomy after PG requires careful consideration of curability and surgical invasiveness. It is crucial to devise reconstruction techniques that minimize tension on the D-J anastomosis.

01 Dec 2024·Surgical Clinics of North America

Cholangiocarcinoma

Review

Author: Visser, Brendan C ; Harrison, Jon M. ; Harrison, Jon M ; Visser, Brendan C.

Management of intrahepatic cholangiocarcinoma relies on a thorough understanding of the tumor's location and proximity to critical vasculobiliary structures. Mid-common bile duct tumors may require hemihepatectomy or pancreatoduodenectomy based on the status of the intraoperative frozen section. Distal common bile tumors are treated with pancreatoduodenectomy. When appropriate, volumetric assessment of the remnant liver should be performed to identify cases requiring preoperative liver augmentation strategies. A similar strategy should be employed for perihilar tumors, which require a right trisegmentectomy with bilioenteric reconstruction to achieve a negative margin. Adjuvant systemic therapy is recommended and increasing usage of neoadjuvant treatment is being incorporated into borderline resectable or regionally advanced cases.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Distal Bile Duct Adenocarcinoma

Basic Info

Related

Analysis